Skip links and keyboard navigation

Cook Medical Australia is capitalising on its success by strengthening relationships and expertise in Queensland’s biomed sector.

Cook Medical Australia is one of Queensland’s leading advanced manufacturers, yet some of its most important and delicate work is done by hand: its custom-made endovascular stents are stitched together by technicians whose delicate and precision work plays a key role in improving patient outcomes.

Located in Brisbane Technology Park at Eight Mile Plains, ‘It is one of the few facilities in the world where these devices are custom made to suit an individual patient’s anatomy,’ explains Cook Medical Australia’s General Manager Dr Samih Nabulsi.

Focusing on patients, quality and innovation has enabled Cook Medical Australia to grow from a distributor of medical devices to a leading developer and manufacturer of world-class endovascular stents and IVF technologies.

Cook Medical Australia’s Brisbane facility focuses on research, development and manufacturing activities in Australia and the Asia-Pacific and employs 461 people. In 2016, the company manufactured more than 13,000 stent grafts for the treatment of aortic aneurysms, and more than 920,000 needles to assist in the reproductive health process. Over 90 per cent of these products were exported to 64 countries at a value exceeding US$100 million.

To facilitate growth in the local biomedical industry, Cook Medical Australia committed $4 million to expand its Eight Mile Plains facility and establish the Asia-Pacific Commercialisation and Development Centre (ACDC).

Opened in February 2017, the ACDC brings together researchers, entrepreneurs and businesses from across the Asia-Pacific region to develop and commercialise new medical products and technologies. Through the ACDC, Cook Medical Australia is mentoring participants by sharing several decades of expertise in product development and commercialisation.

The ACDC is an investment in Queensland’s biomedical future and represents Cook Medical Australia’s long-term commitment to strengthening collaboration between research and industry, developing skills and experience in commercial operations, and increasing business investment and export capabilities in Queensland.

The company is also scouting for new technology throughout the Asia-Pacific region. The Asia-Pacific New Technologies Team (ANTT) was formed in 2014 to discover and evaluate new concepts and technologies from this region and to channel these to appropriate divisions within Cook Medical.

James Macnaughtan, Cook Medical’s Director of New Technologies in Australia and the Asia-Pacific, says ANTT engages with universities, research institutes, start-ups and clinicians to identify suitable technologies that have potential for commercial success. ‘Over 500 concepts have been reviewed by ANTT and 11 are currently being invested in through our business units.’

Cook Medical Australia’s continued investment in Queensland reflects its belief that the state offers significant advantages, including world-class research and education institutions, proximity to transport infrastructure, and economic opportunities.

This is supported by the Queensland Government’s recent announcement that it will invest $4 million to expand Queensland’s biomedical sector and deliver up to 3000 new jobs. The announcement was made by Premier Annastacia Palaszczuk at the BIO international convention in San Diego on 20 June 2017, as part of the launch of the Queensland Biomedical 10-Year Roadmap and Action Plan.

The Queensland biomedical industry has the potential to grow by almost 40% and add $2 billion in annual value to the Queensland economy by 2027. State Development Minister Anthony Lynham said the roadmap will position Queensland biomedical enterprises for rapid technological advances and a strong investment environment.

Subscribe



Share this story